Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Joshua J Gagne, Sc.D., Pharm.D.

Co-Author

This page shows the publications co-authored by Joshua Gagne and Aaron Kesselheim.
Connection Strength

11.777
  1. Gagne JJ, Polinski JM, Jiang W, Dutcher SK, Xie J, Lii J, Fulchino LA, Kesselheim AS. Correction to: Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence. Drugs. 2018 03; 78(4):523-524.
    View in: PubMed
    Score: 0.819
  2. Gagne JJ, Polinski JM, Jiang W, Dutcher SK, Xie J, Lii J, Fulchino LA, Kesselheim AS. Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence. Drugs. 2017 Mar; 77(4):427-433.
    View in: PubMed
    Score: 0.764
  3. Kesselheim AS, Eddings W, Raj T, Campbell EG, Franklin JM, Ross KM, Fulchino LA, Avorn J, Gagne JJ. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval. PLoS One. 2016; 11(10):e0163339.
    View in: PubMed
    Score: 0.745
  4. Kesselheim AS, Gagne JJ. Prescription Trends-Brand-Name Drugs vs Generic-Reply. JAMA Intern Med. 2016 10 01; 176(10):1574-1575.
    View in: PubMed
    Score: 0.742
  5. Gagne JJ, Polinski JM, Jiang W, Dutcher SK, Xie J, Lii J, Fulchino LA, Kesselheim AS. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence. Pharmacoepidemiol Drug Saf. 2016 08; 25(8):944-52.
    View in: PubMed
    Score: 0.720
  6. Kesselheim AS, Gagne JJ. Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness. Drug Saf. 2015 Oct; 38(10):849-53.
    View in: PubMed
    Score: 0.693
  7. Kesselheim AS, Polinski JM, Fulchino LA, Isaman DL, Gagne JJ. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes. Drugs. 2015 Apr; 75(6):633-50.
    View in: PubMed
    Score: 0.669
  8. Kesselheim AS, McGraw S, Thompson L, O'Keefe K, Gagne JJ. Development and use of new therapeutics for rare diseases: views from patients, caregivers, and advocates. Patient. 2015 Feb; 8(1):75-84.
    View in: PubMed
    Score: 0.661
  9. Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014 Nov 24; 349:g6802.
    View in: PubMed
    Score: 0.653
  10. Kesselheim AS, Gagne JJ. Introduction to a supplement on innovative approaches to studying health outcomes in rare diseases. J Gen Intern Med. 2014 Aug; 29 Suppl 3:S709-11.
    View in: PubMed
    Score: 0.639
  11. Kesselheim AS, Gagne JJ. Strategies for postmarketing surveillance of drugs for rare diseases. Clin Pharmacol Ther. 2014 Mar; 95(3):265-8.
    View in: PubMed
    Score: 0.607
  12. Rome BN, Gagne JJ, Avorn J, Kesselheim AS. Non-Warfarin Oral Anticoagulant Copayments and Adherence in Atrial Fibrillation:A Population-Based Cohort Study. Am Heart J. 2020 Dec 21.
    View in: PubMed
    Score: 0.249
  13. Sarpatwari A, He M, Tessema FA, Gagne JJ, Kesselheim AS. Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. Drug Saf. 2020 Nov 18.
    View in: PubMed
    Score: 0.247
  14. Feldman WB, Gagne JJ, Kesselheim AS. Trends in Medicare Part D Inhaler Spending, 2012-2018. Ann Am Thorac Soc. 2020 Nov 18.
    View in: PubMed
    Score: 0.247
  15. Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Med. 2019 03; 16(3):e1002763.
    View in: PubMed
    Score: 0.220
  16. Sarpatwari A, Gagne JJ, Lu Z, Campbell EG, Carman WJ, Enger CL, Dutcher SK, Jiang W, Kesselheim AS. A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. J Gen Intern Med. 2019 03; 34(3):420-428.
    View in: PubMed
    Score: 0.217
  17. Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly J, Fischer MA, Kesselheim AS, Gagne JJ. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ. 2018 Apr 03; 361:k1180.
    View in: PubMed
    Score: 0.206
  18. Sarpatwari A, Lee MP, Gagne JJ, Lu Z, Dutcher SK, Jiang W, Campbell EG, Kesselheim AS. Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. Clin Pharmacol Ther. 2018 06; 103(6):1093-1099.
    View in: PubMed
    Score: 0.201
  19. Mostaghim SR, Gagne JJ, Kesselheim AS. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study. BMJ. 2017 Sep 07; 358:j3837.
    View in: PubMed
    Score: 0.198
  20. Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Campbell EG. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process. Pharmacoepidemiol Drug Saf. 2017 Jun; 26(6):694-701.
    View in: PubMed
    Score: 0.192
  21. Sarpatwari A, Gagne JJ, Levidow NL, Kesselheim AS. Active Surveillance of Follow-on Biologics: A Prescription for Uptake. Drug Saf. 2017 02; 40(2):105-108.
    View in: PubMed
    Score: 0.190
  22. Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. Eur J Cancer. 2017 01; 70:22-33.
    View in: PubMed
    Score: 0.187
  23. Kesselheim AS, Bykov K, Gagne JJ, Wang SV, Choudhry NK. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study. Neurology. 2016 Oct 25; 87(17):1796-1801.
    View in: PubMed
    Score: 0.185
  24. Luo J, Seeger JD, Donneyong M, Gagne JJ, Avorn J, Kesselheim AS. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending. JAMA Intern Med. 2016 09 01; 176(9):1317-23.
    View in: PubMed
    Score: 0.185
  25. Kesselheim AS, Gagne JJ, Eddings W, Franklin JM, Ross KM, Fulchino LA, Campbell EG. Prevalence and Predictors of Generic Drug Skepticism Among Physicians: Results of a National Survey. JAMA Intern Med. 2016 06 01; 176(6):845-7.
    View in: PubMed
    Score: 0.181
  26. Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Avorn J, Campbell EG. Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey. J Gen Intern Med. 2016 06; 31(6):609-14.
    View in: PubMed
    Score: 0.178
  27. Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015 Nov; 52(Pt A):14-8.
    View in: PubMed
    Score: 0.173
  28. Wang B, Choudhry NK, Gagne JJ, Landon J, Kesselheim AS. Availability and utilization of cardiovascular fixed-dose combination drugs in the United States. Am Heart J. 2015 Mar; 169(3):379-386.e1.
    View in: PubMed
    Score: 0.165
  29. Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014 Sep 16; 161(6):400-7.
    View in: PubMed
    Score: 0.161
  30. Gagne JJ, Polinski JM, Kesselheim AS, Choudhry NK, Hutchins D, Matlin OS, Tong A, Shrank WH. Patterns and predictors of generic narrow therapeutic index drug use among older adults. J Am Geriatr Soc. 2013 Sep; 61(9):1586-91.
    View in: PubMed
    Score: 0.150
  31. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010 Mar 26; 70(5):605-21.
    View in: PubMed
    Score: 0.118
  32. Barenie RE, Kesselheim AS, Gagne JJ, Lu Z, Campbell EG, Dutcher SK, Jiang W, Sarpatwari A. Preferences for and experiences with pill appearance changes: national surveys of patients and pharmacists. Am J Manag Care. 2020 08; 26(8):340-347.
    View in: PubMed
    Score: 0.061
  33. Barenie RE, Gagne JJ, Kesselheim AS, Pawar A, Tong A, Luo J, Bateman BT. Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018. Drug Saf. 2020 07; 43(7):669-675.
    View in: PubMed
    Score: 0.060
  34. Rogers JR, Sarpatwari A, Desai RJ, Bohn JM, Khan NF, Kesselheim AS, Fischer MA, Gagne JJ, Connolly JG. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Drug Saf. 2019 01; 42(1):85-93.
    View in: PubMed
    Score: 0.054
  35. Sarpatwari A, Kesselheim AS, Malin BA, Gagne JJ, Schneeweiss S. Ensuring patient privacy in data sharing for postapproval research. N Engl J Med. 2014 Oct 23; 371(17):1644-9.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.